As a result, we were able to clearly evaluate exon-skipping in a dose-dependent manner at the mRNA (Fig. 5A) and protein (Fig. 5B) level using DZNep-treated MYOD1-UDCs from these DMD patients. This evidence concerns the gene MYOD1 and Duchenne muscular dystrophy.